[
    [
        {
            "time": "2018-01-01",
            "original_text": "Tresiba Could Significantly Drive Novo Nordisk’s Revenue in 2018",
            "features": {
                "keywords": [
                    "Tresiba",
                    "Significantly Drive",
                    "Novo Nordisk",
                    "Revenue"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Tresiba Could Significantly Drive Novo Nordisk’s Revenue in 2018",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-01",
            "original_text": "Ozempic Could Be Potential Driver for Novo Nordisk in 2018",
            "features": {
                "keywords": [
                    "Ozempic",
                    "Potential Driver",
                    "Novo Nordisk"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Ozempic Could Be Potential Driver for Novo Nordisk in 2018",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-01",
            "original_text": "This Small Biotech Is Building on a Surprising Success",
            "features": {
                "keywords": [
                    "Small Biotech",
                    "Building",
                    "Surprising Success"
                ],
                "sentiment_score": 0.65,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "This Small Biotech Is Building on a Surprising Success",
                "Correlation": 4,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        }
    ]
]